BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Tatva Chintan Pharma Chem Ltd.’s Q4 FY22 Ebitda came in ~12% below our estimate mainly on account of subdued growth in structure-directing agents due to semiconductor chip shortage globally.
As a result, Ebitda margin also came slightly lower sequentially as SDAs enjoy high margins. Management expects the chip shortage issue to continue to impact SDAs’ growth for two more quarters as customers are postponing orders.
However, the underlying demand is still robust. Other segments maintained the growth trajectory.
During the quarter, Tatva Chintan was able to pass on the input cost and freight cost burden to majority of its key clients, including new ones.
In pharma and agrochemicals specialty chemicals segment, Tatva Chintan is working on multiple new products apart from Monoglyme, which should enable strong growth in this segment in the coming years.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
